secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2026-05-27T20:01:51+00:00
Accession:  0001193125-26-241846
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio raises $55M in PIPE financing; proceeds for bempikibart trials
----------------------------------------------------------------------

- Gross proceeds ~$55M from sale of 6.725M shares at $8.00 and pre-funded warrants for 150K shares.
- Investors include BVF Partners, RA Capital, OrbiMed, Atlas Venture; led by BVF.
- Closing expected May 28, 2026; net proceeds to advance bempikibart clinical trials and for working capital.
- Registration rights agreement filed to register resale of shares and warrant shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526241846/0001193125-26-241846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312526241846/d228038d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-241846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer